Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by strong sales of drugs like Mounjaro and Zepbound. Analysts project further upside with a price target of $1,378.50, reflecting confidence in Lilly's pipeline including upcoming retatrutide filings. Risks include pricing pressure and ongoing litigation, but overall growth momentum supports a buy rating with 90% confidence.
As of Oct 13, 2026 23:41 WIB, Eli Lilly (LLY) trades at USD 1,169.00 on Pluang, down 1.15% for the day with a market cap of $1.05 trillion. Compared to its peers, Novo Nordisk (NVO) and AbbVie (ABBV), which also saw declines of 1.01% and 1.92% respectively, Lilly's enterprise value stands at $1.10 trillion. Despite the recent price dip, Pluang users show a majority sell sentiment at 71%, while typical holding periods for Lilly shares are 93 days, highlighting active trading interest in this high-growth pharma stock.
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
